Valproate population pharmacokinetics in children

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 1, 1999, Pages 73-80

  Serrano, B Blanco ^a   Sánchez, M J García ^b   Otero, M J ^a   Buelga, D Santos ^b   Serrano, J ^a   Dominguez Gil A ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ADOLESCENT; AGE; ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEDIATRICS; SEX;

ADOLESCENT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; HUMANS; INFANT; MODELS, THEORETICAL; VALPROIC ACID;

EID: 0032905806     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00202.x     Document Type: Article

References (26)

1. 1. Davis R, Peters DV, McTavish D. (1994) Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs, 47, 332-372.
2. 2. Bourgeois BFD. (1995) Antiepileptic drugs in pediatric practice. Epilepsia, 36, S34-S45.
3. 3. Cloyd JC, Fisher JH, Kriel RL, Kraus DM. (1993) Valproic acid pharmacokinetics in children. IV: Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clinical Pharmacology and Therapeutics, 53, 22-29.
4. 4. Bowdle TA, Patel IH, Levy RH. (1980) Valproic acid dosage and plasma protein binding and clearance. Journal of Clinical Pharmacy and Therapeutics, 28, 486-492.
5. 5. Tisdale JE, Tsuyuki RT, Oles KS, Penry JK. (1992) Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients. Therapeutic Drug Monitoring, 14, 416-243.
6. 6. Gidal BE, Pitterle ME, Spencer NW, Maly MM. (1995) Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. Clinical Pharmacology and Therapeutics, 20, 215-219.
7. 7. Sundqvist A, Tomson T, Lundkvist B. (1997) Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Therapeutic Drug Monitoring, 19, 153-159.
8. 8. Yukawa E. (1996) Optimisation of antiepileptic drug therapy. Clinical Pharmacokinetics, 31, 120-310.
9. 9. Beal SL, Sheiner LB. (1992) Nonmem User's Guides. NONMEM Project Group, University of California, San Francisco.
10. 10. Riva R, Albani F, Contin M, Baruzzi A. (1996) Pharmacokinetic interactions between antiepileptic drugs: clinical considerations. Clinical Pharmacokinetics, 31, 470-493.
11. 11. Perucca E, Gatti G, Frigo GM, Crema A. (1978) Disposition of sodium valproate in epileptic patients. British Journal of Clinical Pharmacology, 5, 313-318.
12. 12. Botha JH, Gray AL, Miller R. (1995) A model for estimating individualized valproate clearance values in children. Journal of Clinical Pharmacology, 35, 1020-1024.
13. 13. Rowland M, Tozer TN. (1989) Clinical Pharmacokinetics: Concepts and Applications, 2nd edn. Lea and Febiger, Philadelphia.
14. 14. Sheiner LB, Beal SL. (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503-512.
15. 15. Vozeh S, Maitre PO, Stanski DR. (1990) Evaluation of population (Nonmem) pharmacokinetic parameter estimates. Journal of Pharmacokinetics and Biopharmaceutics, 18, 161-173.
16. 16. Levy RH, Koch KM. (1982) Drug interactions with valproic acid. Drugs, 24, 543-556.
17. 17. Chiba K, Suganuma T, Ishizaki T, et al. (1985) Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. Journal of Pediatrics, 106, 653-665.
18. 18. Hall K, Otten N, Johnston B, Irvine-Meek J, Leroux M, Seshia S. (1985) A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. Journal of Clinical Pharmacology, 25, 261-268.
19. 19. Hall K, Otten N, Irvine-Meek J, Leroux M, Budnick D, et al. (1983) First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. Clinical Pharmacokinetics, 8, 447-455.
20. 20. Yukawa E. (1995) A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. Journal of Pharmacy and Pharmacology, 47, 1048-1052.
21. 21. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. (1997) Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. Journal of Clinical Pharmacology, 37, 1160-1167.
22. 22. Suzuki Y, Cox S, Hayes J, Walson PD. (1991) Carbamazepine age-dose ratio relationship in children. Therapeutic Drug Monitoring, 13, 201-208.
23. 23. Martin ES, Crismon ML, Godley PJ. (1991) Postinduction carmamazepine clearance in an adult psychiatric population. Pharmacotherapy, 1, 296-302.
24. 24. Henriksen O, Johannessen SL. (1982) Clinical and pharmacokinetic observations on sodium valproate: a five-year follow-up study in 100 children with epilepsy. Acta Neurological Scandinavica, 65, 504-523.
25. 25. Cloyd JC, Kriel RL, Fisher JH. (1985) Valproic acid pharmacokinetics in children: II. Discontinuation of concomitant antiepileptic drug therapy. Neurology, 35, 1623-1627.
26. 26. Panesar SK, Orr JM, Farrell K, Burton RW, Kassahun K, Abbott FS. (1989) The effect of carbamazepine on valproic acid disposition in adult volunteers. British Journal of Clinical Pharmacology, 27, 323-328.